Van ECK Associates Corp Has $56.51 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Van ECK Associates Corp raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 13.2% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 64,337 shares of the biopharmaceutical company’s stock after buying an additional 7,509 shares during the quarter. Van ECK Associates Corp owned 0.06% of Regeneron Pharmaceuticals worth $56,507,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. FMR LLC boosted its holdings in Regeneron Pharmaceuticals by 7.3% in the third quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company’s stock worth $8,098,661,000 after purchasing an additional 669,517 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Regeneron Pharmaceuticals by 3.3% during the 3rd quarter. Northern Trust Corp now owns 1,067,210 shares of the biopharmaceutical company’s stock worth $878,271,000 after acquiring an additional 34,326 shares in the last quarter. Morgan Stanley increased its holdings in shares of Regeneron Pharmaceuticals by 2.7% during the 3rd quarter. Morgan Stanley now owns 970,957 shares of the biopharmaceutical company’s stock valued at $799,061,000 after acquiring an additional 25,792 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Regeneron Pharmaceuticals by 0.3% in the 3rd quarter. Bank of New York Mellon Corp now owns 967,414 shares of the biopharmaceutical company’s stock valued at $796,142,000 after acquiring an additional 2,666 shares in the last quarter. Finally, American Century Companies Inc. lifted its holdings in Regeneron Pharmaceuticals by 3.4% in the 3rd quarter. American Century Companies Inc. now owns 916,718 shares of the biopharmaceutical company’s stock worth $754,422,000 after purchasing an additional 30,050 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Morgan Stanley raised their price target on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a research report on Wednesday, March 13th. Cantor Fitzgerald reissued a “neutral” rating and issued a $925.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Monday, April 15th. Barclays boosted their target price on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 23rd. BMO Capital Markets raised their price target on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an “outperform” rating in a research report on Monday, February 5th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $1,189.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 9th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $977.77.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock traded up $2.78 on Tuesday, reaching $895.26. The company had a trading volume of 116,968 shares, compared to its average volume of 484,983. The company has a quick ratio of 4.94, a current ratio of 5.69 and a debt-to-equity ratio of 0.10. The stock has a market capitalization of $98.26 billion, a PE ratio of 25.68, a price-to-earnings-growth ratio of 2.54 and a beta of 0.11. Regeneron Pharmaceuticals, Inc. has a one year low of $684.80 and a one year high of $998.33. The business’s 50-day moving average is $946.89 and its 200 day moving average is $894.83.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, beating analysts’ consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The business had revenue of $3.43 billion during the quarter, compared to the consensus estimate of $3.29 billion. During the same period in the prior year, the business posted $10.96 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up .6% on a year-over-year basis. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 38.8 EPS for the current fiscal year.

Insider Transactions at Regeneron Pharmaceuticals

In other news, EVP Marion Mccourt sold 1,000 shares of the firm’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $934.71, for a total value of $934,710.00. Following the completion of the sale, the executive vice president now directly owns 13,789 shares in the company, valued at approximately $12,888,716.19. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other news, EVP Marion Mccourt sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $934.71, for a total transaction of $934,710.00. Following the completion of the transaction, the executive vice president now directly owns 13,789 shares in the company, valued at $12,888,716.19. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $954.22, for a total transaction of $95,422.00. Following the completion of the sale, the director now owns 18,382 shares in the company, valued at approximately $17,540,472.04. The disclosure for this sale can be found here. In the last ninety days, insiders sold 10,195 shares of company stock valued at $9,759,898. Corporate insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.